UCB appoints Steve Turley as managing director for British Isles and Ireland

16 November 2015

Belgian pharma major UCB (Euronext: UCB) has appointed Steve Turley as managing director for the UK and Ireland.

He brings more than 20 years of commercial experience in biopharma, having worked across primary and specialty therapy areas at local and international levels. Mr Turley has worked at Merck (NYSE: MRK), Roche (SIX: ROG) and joins UCB from Lundbeck, where he was managing director for Lundbeck UK & Ireland.

Mr Turley said: “I am pleased to be joining a dynamic business that is focused on delivering medicines that really deliver for patients. I am looking forward to building on that with our team here in the British Isles and Ireland.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK